Lodz

• A Multicenter trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects with Moderate-to-Severe Atopic … Ended
  2024-514405-65-00 4 2021-11-22 Atopic Dermatitis
• A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509782-20-00 4 2021-11-11 Diffuse Cutaneous Systemic Sclerosis
• A study to evaluate the efficacy and safety of repeating dose of benralizumab administered SC versus placebo in patients with Eosinophilic C … Ended
  2023-507987-38-00 5 2021-10-14 Severe CRSwNP patients with asthma.
• Efficacy and safety of obinutuzumab versus rituximab in combination with chemotherapy for adult patients with newly diagnosed CD20-positive … Ended
  2024-517389-40-00 4 2021-10-06 acute lymphoblastic leukemia
• A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended
  2023-509741-12-00 4 2021-09-23 Ulcerative Colitis
• A study to learn how safe bimekizumab, how well it works and how it moves through the bloodstream in adolescents with moderate to severe pla … Ended
  2023-509832-24-00 4 2021-08-30 Moderate to Severe Plaque Psoriasis
• A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration Ended
  2024-512880-30-00 5 2021-08-27 Neovascular Age-related Macular Degeneration (wet AMD)
• A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disea … Ended
  2023-504156-10-00 5 2021-08-13 Plaque Psoriasis.
• A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended
  2023-505203-23-01 5 2021-07-26 Severe asthma with an eosinophilic phenotype
• Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathi … Ended
  2024-515964-30-00 4 2021-07-14 Interstitial Lung Diseases (ILD), including but not limited to idiopat
• A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan … Ended
  2024-513569-38-00 10 2021-07-09 Crohn's Disease
• The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended
  2023-510174-13-00 5 2021-06-17 Chronic Obstructive Pulmonary Disease (COPD)
• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 5 2021-06-16 Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
• EASE SBS 3 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome (SBS) Ended
  2024-513373-43-00 5 2021-06-11 Short bowel syndrome
• A Study of BMS-986012 in Combination with Carboplatin, Etoposide, andNivolumab as First-line Therapy in Extensive-stage Small Cell Lung Canc … Ended
  2024-510700-36-00 4 2021-06-01 Extensive-stage Small Cell Lung Cancer
• A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab … Ended
  2023-507317-10-00 5 2021-05-10 Locally advanced, unresectable, or metastatic non small cell lung canc
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended
  2023-507977-16-00 4 2021-05-10 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
• Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-P … Ended
  2023-509698-21-00 5 2021-03-17 Prevention of post abdominal surgery incisional infection.
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C … Ended
  2022-502031-20-00 10 2020-12-17 Non-squamous non-small cell lung cancer (NSCLC)
• TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended
  2023-505894-33-00 4 2020-11-25 Lung Cancer, Non-Small Cell
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approv … Ended
  2023-507493-41-00 5 2020-08-04 relapsing multiple sclerosis (RMS)

Showing 841–864 of 898 trials